Michael Vogeser
Overview
Explore the profile of Michael Vogeser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
217
Citations
2436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wustrow V, Grafe C, Graf H, Scheiermann P, Paal M, Vogeser M, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002832
: Patients with shock suffer from hyperlactatemia, which can lead to endothelial dysfunction. The use of the adsorber Cytosorb (CS) is recommended in these patients as it may contribute to...
2.
Wormann B, Kopp I, Nothacker M, Klar E, Sedlmayr M, Vogeser M, et al.
Ger Med Sci
. 2024 Dec;
22:Doc10.
PMID: 39669398
Objective: After over 25 years of developing clinical practice guidelines, the Association of the Scientific Medical Societies in Germany (AWMF) held a symposium to discuss the following topics in order...
3.
Vogeser M, Habler K, Reuter A, Schneider-Thauern C
J Mass Spectrom Adv Clin Lab
. 2024 Nov;
34:44-45.
PMID: 39584148
No abstract available.
4.
Kahles A, Goldschmid H, Volckmar A, Kazdal D, Gassner U, Vogeser M, et al.
Ger Med Sci
. 2024 Nov;
22:Doc09.
PMID: 39559338
Institutes for pathology act as operators, users and in-house manufacturers of in vitro diagnostic medical devices and are subject to national and European regulations depending on their function. The entry...
5.
Wicha S, Kinast C, Munchow M, Wittova S, Greppmair S, Kunzelmann A, et al.
Antimicrob Agents Chemother
. 2024 Nov;
68(12):e0146824.
PMID: 39503486
No abstract available.
6.
Naehrig S, Shad C, Breuling M, Goetschke M, Habler K, Sieber S, et al.
J Pers Med
. 2024 Oct;
14(10).
PMID: 39452571
Background/objectives: Elexacaftor, tezacaftor, and ivacaftor (ETI) have significantly improved lung function in people with cystic fibrosis (pwCF). Despite exceptional improvements in most cases, treatment-related inter-subject variability and drug-drug interactions that...
7.
Habler K, Rexhaj A, Adling-Ehrhardt M, Vogeser M
J Mass Spectrom Adv Clin Lab
. 2024 Sep;
33:49-54.
PMID: 39279892
Mass spectrometry (MS) is a versatile analytical tool used in various fields such as biochemistry, pharmacology, omics, and clinical analysis for determining and quantifying compounds based on their molecular mass...
8.
Schaffler J, Vogeser M, Habler K
J Mass Spectrom Adv Clin Lab
. 2024 Sep;
33:43-48.
PMID: 39279891
Background: Reference measurement procedures are an essential element in the standardization and comparability of analytical measurement results in laboratory medicine. No LC-MS/MS-based reference measurement procedure for cefepime in serum has...
9.
Standardization via Post Column Infusion-A Novel and Convenient Quantification Approach for LC-MS/MS
Habler K, Rexhaj A, Happich F, Vogeser M
Molecules
. 2024 Aug;
29(16).
PMID: 39202908
Mass spectrometry (MS) is a widely used analytical technique including medical diagnostics, forensic toxicology, food and water analysis. The gold standard for quantifying compounds involves using stable isotope-labeled internal standards...
10.